Abstract
Polycystic ovary syndrome (PCOS) is highly associated with the metabolic syndrome (MetS): Obesity, insulin resistance and atherogenic dyslipidemia. First-line intervention in PCOS-MetS includes targeting diet and lifestyle, and metformin is commonly prescribed to treat insulin resistance. However, these interventions have shown limited effectiveness to improve dyslipidemia. Fish oil (FO) can reduce plasma triglycerides (TG), however, the efficacy of FO as an adjunct therapy to metformin to improve ApoB-remnant lipemia in PCOS-MetS is unknown.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
